title: Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
abstract: OBJECTIVE
  We previously reported that a single preprandial injection (120 microg) of pramlintide, an analog of the beta-cell hormone amylin, reduced ad libitum food intake in obese subjects. To further characterize the meal-related effects of amylin signaling in humans, we studied a lower pramlintide dose (30 microg) in normal-weight subjects.
  
  
  METHODS
  In a randomized, double-blind, placebo-controlled, cross-over study, 15 healthy men (age, 24 +/- 7 years; BMI, 22.2 +/- 1.8 kg/m(2)) underwent a standardized buffet meal test on two occasions. After an overnight fast, subjects received a single subcutaneous injection of pramlintide (30 microg) or placebo, followed immediately by a standardized pre-load meal. After 1 hour, subjects were offered an ad libitum buffet meal, and total caloric intake and meal duration were measured.
  
  
  RESULTS
  Compared with placebo, pramlintide reduced total caloric intake (1411 +/- 94 vs. 1190 +/- 117 kcal; Delta, -221 +/- 101 kcal; -14 +/- 9%; p = 0.05) and meal duration (36 +/- 2 vs. 31 +/- 3 minutes; Delta, -5.1 +/- 1.4 minutes; p < 0.005). Visual analog scale profiles of hunger trended lower and fullness higher during the first hour after pramlintide administration. In response to the buffet, hunger and fullness changed to a similar degree after pramlintide and placebo, despite subjects on pramlintide consuming 14% fewer kilocalories. Visual analog scale nausea ratings remained near baseline, without differences between treatments. Plasma peptide YY, cholecystokinin, and ghrelin concentrations did not differ with treatment, whereas glucagon-like peptide-1 concentrations after meals were lower in response to pramlintide than to placebo.
  
  
  CONCLUSIONS
  These observations add support to the concept that amylin agonism may have a role in human appetite control.
authors.affiliation: Department of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, Australia.
authors.forename: Ian
authors.initials: I
authors.lastname: Chapman
authors.forename: Barbara
authors.initials: B
authors.lastname: Parker
authors.forename: Selena
authors.initials: S
authors.lastname: Doran
authors.forename: Christine
authors.initials: C
authors.lastname: Feinle-Bisset
authors.forename: Judith
authors.initials: J
authors.lastname: Wishart
authors.forename: Cameron W
authors.initials: CW
authors.lastname: Lush
authors.forename: Kim
authors.initials: K
authors.lastname: Chen
authors.forename: Carl
authors.initials: C
authors.lastname: Lacerte
authors.forename: Colleen
authors.initials: C
authors.lastname: Burns
authors.forename: Robyn
authors.initials: R
authors.lastname: McKay
authors.forename: Christian
authors.initials: C
authors.lastname: Weyer
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
mesh_terms: D000328:Adult; D000368:Aged; D000682:Amyloid / Q000494:pharmacology*; D015992:Body Mass Index; D001835:Body Weight; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004435:Eating / Q000502:physiology*; D002149:Energy Intake / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D058228:Islet Amyloid Polypeptide; D008297:Male; D008875:Middle Aged; D010919:Placebos; D019518:Postprandial Period; D012016:Reference Values; D013997:Time Factors
chemical_list: D000682:Amyloid; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D010919:Placebos; C105254:pramlintide